NCT05639530View on ClinicalTrials.gov

A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

December 7, 2023

Study Completion Date

April 23, 2024

Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

IBI333

Intravitreal injection of IBI333

Trial Locations (1)

101199

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY